PRODUCTS
Oncofibro offers precision-engineered solutions designed to support advanced cell and gene therapy development, as well as animal health research.
Krysaygio™
Krysaygio™ is an autologous immune-cell therapy
designed to transiently enhance the function of dysfunctional immune
cells through ex vivo exposure to an immune-modulating recombinant
protein.
In this approach, a patient’s own blood is collected and processed
under controlled conditions. Immune cells are treated ex vivo with
Tatmyctofusp before being reinfused into the same patient. This
brief exposure induces a temporary increase in MYC-dependent
signaling — a central regulator of cellular metabolism and function
that may be suppressed in exhausted or dysfunctional immune cells.
The result is enhanced metabolic capacity, cytokine production, and
cytotoxic potential without genetic modification or exogenous IL-2
administration.
Krysaygio™ is administered intravenously, typically as a series of
infusions given at defined intervals under clinical supervision.
Early clinical experience abroad has generated encouraging
observations. The therapy has received conditional authorization in
Japan under the country’s regulatory framework for autologous
regenerative medicine products, while remaining investigational in
other jurisdictions. Clinical trial preparations are underway in
Singapore.
Where permitted under applicable regulations, access may be
available through physician-led compassionate use pathways.
Clinicians or centres interested in participation may contact us at:
[email protected]
Treactivus™
Treactivus™ is an in vivo immunotherapeutic solution administered by subcutaneous injection for the treatment of cancers and difficult‑to‑manage or treatment‑resistant infections in animals. Early clinical use has demonstrated a favorable safety profile and encouraging effectiveness across multiple cases. Developed for companion animals, racing animals, and working dogs—including police (K‑9) and military canines—Treactivus™ is designed to support immune recovery and improve outcomes in high‑value and high‑demand animal populations.
Tatmyctotrans™
Tatmyctotrans™ is the ancillary counterpart to Tatmyctofusp and is
specifically designed to revive anergic or exhausted immune cells,
enhancing their functionality prior to manufacturing steps for
mRNA‑T, CAR‑T, and NK‑cell therapies, with particular value in
autologous workflows.
By rescuing immune cells that have been
weakened by chemotherapy, radiation, checkpoint inhibitors,
antibody–drug conjugates, or virus‑associated cancers such as EBV or
Hepatitis, Tatmyctotrans™ enables more efficient genetic
engineering, activation, and ex vivo expansion—helping ensure robust
starting material for advanced cell‑therapy manufacturing.
Tatmyctotrans™ is available in RUO, clinical‑grade, and commercial
GMP‑grade formats, supporting use across research, development, and
regulated manufacturing environments. It serves as a critical
ancillary starting material in the production of autologous cell
therapies. Although not present in the final product, it plays an
essential role in restoring the fitness and responsiveness of
patient‑derived immune cells before genetic modification and
expansion.
